Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline.
PR Newswire Europe, March, 2008
NOVATO, California, March 19 /PRNewswire/ --
- Acquires Rights from UCSD to Develop Cysteamine for the Treatment of NASH
- Enters Convivia(TM) Formulation and Manufacturing Agreement with Patheon Pharmaceuticals
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego ("UCSD") around the use of Cysteamine, and Delayed Release Cysteamine ("DR Cysteamine") for the treatment of Non-alcoholic Steatohepatitis ("NASH"). In collaboration with doctors from UCSD School of Medicine, Bennu plans to initiate a...
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Design a commission plan that drives sales - Sales Commissions
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
